HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
企業コードHSCS
会社名HeartSciences Inc
上場日Jun 15, 2022
最高経営責任者「CEO」Mr. Andrew Simpson
従業員数15
証券種類Ordinary Share
決算期末Jun 15
本社所在地550 Reserve St, Suite 360
都市SOUTHLAKE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号76092
電話番号16822377781
ウェブサイトhttps://heartsciences.com/
企業コードHSCS
上場日Jun 15, 2022
最高経営責任者「CEO」Mr. Andrew Simpson
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし